Boston Children's Researchers Find "Cancer-Like" Mutations in Brain Immune Cells May Be a Primary Driver of Alzheimer's

Boston Children's study finds Alzheimer's is driven by cancer-like mutations in brain immune cells, potentially allowing cancer drugs to treat dementia.

By: AXL Media

Published: Apr 22, 2026, 4:56 AM EDT

Source: Information for this report was sourced from Boston Children’s Hospital and the journal Cell.

Alzheimer's and Cancer: A Shared Genetic Root While Alzheimer's disease has traditionally been viewed through the lens of protein plaques and tangles, new research from Boston Children’s Hospital introduces a "somatic mutation" theory. The study found that microglia—the brain’s dedicated garbage-collection immune cells—frequently harbor mutations in five specific genes known to drive leukemia and lymphoma. Interestingly, these mutations do not manifest as brain cancer. Instead, they appear to "supercharge" the inflammatory response of microglia, making them toxic to the very neurons they are meant to protect.

The Discovery of Infiltrating Blood Cells In a significant shift in neurobiology, the research team, led by Dr. Christopher Walsh, discovered that these mutations aren't just originating in the brain. By comparing brain tissue samples from 190 Alzheimer’s patients with 121 healthy controls, the team found that the blood of Alzheimer’s patients often carried the exact same cancer-linked mutations. This suggests that immune cells from the blood are crossing a weakened blood-brain barrier, entering the brain, and "disguising" themselves as resident microglia.

A Hostile Takeover in the Brain The researchers theorize that as the brain ages or suffers injury, the blood-brain barrier becomes porous. When protein clumps (like amyloid) begin to form, the brain signals for more immune support. The immune cells with cancer-driving mutations have a "selective advantage," allowing them to proliferate faster than healthy cells. However, these "mutant" microglia are far more aggressive; they trigger chronic inflammation that kills healthy bystander neurons, leading to the cognitive decline characteristic of Alzheimer’s.

New Avenues for Diagnosis and Treatment The link between blood cancer mutations and Alzheimer's provides two major opportunities for the future of medicine:

Early Diagnostics: Since these mutations are detectable in the blood, clinicians may eventually be able to use simple genetic blood screens to identify individuals at high risk for Alzheimer's years before symptoms appear.

Repurposed Therapeutics: "We have a lot of drugs to fight cancer, and some of them might be useful therapeutically for Alzheimer’s disease," said Dr. Walsh. Targeting the specific pathways activated by these mutations could slow or stop the inflammatory destruction of the b...